Circulating Factors in Single Ventricle Heart Disease Impair Cardiomyocyte Bioenergetics, With Partial Rescue by PDE5 Inhibition.
BACKGROUND Although operative and perioperative care continues to improve for patients with single ventricle (SV) congenital heart disease, long-term morbidities and mortality remain high. Importantly, phosphodiesterase-5 inhibitor (PDE5i) therapies are increasingly used, but their direct myocardial effects in SV conge...